BioSim™ anti-Omalizumab (Human) ELISA Kit

(No reviews yet) Write a Review
SKU:
E4395-100
£885.38
Frequently bought together:

Description

BioSim™ anti-Omalizumab (Human) ELISA Kitis available at Gentaur for Next week Delivery.

A Sandwich ELISA kit for the qualitative determination of antibody against Omalizumab in human serum or plasma..

Description:

Omalizumab (Xolair®) is a recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persistent asthma. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision’s BioSimTM anti-Omalizumab ELISA kit is designed to detect antibody against Omalizumab with high specificity and sensitivity in biological matrices.

Applications: This ELISA kit is used for Qualitative determination of antibody against Omalizumab (Xolair) in serum and plasma

Sample Typ:e Human serum and plasma

Alternate Name:

Features and Benefits:

Easy, convenient, sensitive and time-saving method toqualitative determination of antibody against Omalizumab (Xolair) in human serum and plasma. Cross Reactivity: Omalizumab (Xolair®) infusion camouflages/masks the presence of antibody to Omalizumab (ATO) in serum/plasma samples. Therefore, blood sampling time is critical for detection of ATO. It is convenient to obtain blood sample just before the infusion or at least 2 weeks after the infusion of Omalizumab.

View AllClose

Additional Information

Size:
100 assays
Storage Conditions:
4°C4°C
Shipping Conditions:
gel pack
Shelf life:
12 months
Detection Method:
Absorbance (450 nm)
Category:
ELISA
View AllClose

0 Reviews

View AllClose